Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Aug 16, 2021 12:01pm
129 Views
Post# 33710208

Necessity is the Mother of Invention

Necessity is the Mother of Inventionhttps://news.yale.edu/2021/03/22/covid-19-drives-more-severe-form-acute-kidney-injury-yale-study-finds

COVID-19 drives a more severe form of acute kidney injury, Yale study finds


Acute kidney injury is an abrupt decline in the kidney’s filtration function that is typically found in 15% of hospitalized patients and increases a patient’s likelihood of death ten-fold.

For reasons that are still not clear, the condition is more common in patients with COVID-19. Earlier research has shown that 24% to 57% of patients hospitalized with COVID-19 developed AKI. In fact, this latest research suggests that the disease may cause a more serious form of AKI to develop.

...It may be possible, in part, to mitigate this progression by optimizing blood pressure control and making sure any diabetes is well controlled.



With all these increased risks to Covid sufferors, and even Covid hospitalization survivors 9in teh millions in teh US) ....I wonder if there is any way that Spectral can help?  They say that necessity is the mother of invention.  (1) PMX (through endotoxin removal, blood pressure improvments, reduced ventilator use, etc.) and (2)  SAMI (via supply of more portabe, easy to use CRRT's) , and (3) DIMIs (to reduce risk to Dialysis patients, by getting treated in their homes.

MM

<< Previous
Bullboard Posts
Next >>